Ocular Therapeutix Quarterly Balance Sheet
NASDAQ: OCULHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ocular Therapeutix financial position
As of Jun 30, 2026, Ocular Therapeutix reported total assets of $671.3 million, up 48.7% from a year earlier against total liabilities of $151.3 million. Shareholders' equity stood at $520.0 million, or 77.5% of assets. The company held $598.6 million in cash and equivalents against $72.8 million of debt, a net cash position of $525.8 million.
The current ratio (current assets divided by current liabilities) was 13.11, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.14.
Summary generated from market data by MetaCap's automated system. Methodology
Ocular Therapeutix balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 598.64M | 666.70M | 737.06M | 344.77M | 391.13M | 349.68M | 392.10M | 427.22M | 459.69M | 482.89M | 195.81M | 110.55M |
| Receivables | 30.26M | 24.35M | 30.65M | 30.77M | 30.41M | 25.22M | 32.39M | 30.23M | 30.23M | 26.55M | 26.18M | 23.59M |
| Inventory | 3.83M | 3.74M | 3.56M | 3.49M | 3.04M | 3.27M | 3.04M | 2.40M | 2.55M | 2.57M | 2.31M | 2.26M |
| Total Current Assets | 644.43M | 706.00M | 782.13M | 386.98M | 433.38M | 387.69M | 440.99M | 473.01M | 498.58M | 519.82M | 232.24M | 141.26M |
| Property, Plant & Equipment | 19.46M | 18.43M | 19.68M | 16.95M | 10.46M | 10.78M | 9.39M | 10.05M | 10.89M | 11.45M | 11.74M | 12.49M |
| Total Assets | 671.32M | 732.53M | 808.06M | 410.88M | 451.33M | 405.92M | 457.94M | 490.37M | 517.09M | 538.95M | 252.06M | 162.38M |
| Accounts Payable | 7.00M | 8.03M | 4.15M | 6.26M | 5.89M | 4.63M | 4.18M | 4.00M | 3.69M | 6.45M | 4.39M | 3.98M |
| Total Current Liabilities | 49.17M | 47.68M | 50.81M | 49.29M | 42.93M | 37.93M | 41.35M | 36.36M | 29.97M | 24.30M | 34.90M | 35.07M |
| Long-Term Debt | 72.80M | 72.06M | 71.34M | 70.62M | 69.91M | 69.20M | 68.50M | 67.81M | 67.13M | 66.46M | 65.79M | 65.12M |
| Total Liabilities | 151.28M | 150.96M | 153.75M | 152.65M | 145.42M | 139.99M | 142.59M | 138.35M | 139.40M | 130.96M | 160.93M | 154.53M |
| Shareholders' Equity | 520.04M | 581.57M | 654.31M | 258.23M | 305.92M | 265.93M | 315.34M | 352.02M | 377.69M | 407.98M | 91.13M | 7.85M |
| Retained Earnings | -1.32B | -1.25B | -1.16B | -1.09B | -1.02B | -955.14M | -891.08M | -842.70M | -806.20M | -762.43M | -697.58M | -668.36M |
| Total Debt | 72.80M | 72.06M | 71.34M | 70.62M | 69.91M | 69.20M | 68.50M | 67.81M | 67.13M | 66.46M | 65.79M | 65.12M |
| Net Cash (Debt) | 525.85M | 594.64M | 665.72M | 274.15M | 321.23M | 280.48M | 323.60M | 359.40M | 392.56M | 416.43M | 130.02M | 45.43M |
| Shares Outstanding | 219.59M | 218.90M | 215.93M | 174.95M | 172.93M | 159.26M | 157.75M | 156.65M | 155.62M | 154.70M | 114.96M | 79.41M |
This table shows 12 quarterly periods of Ocular Therapeutix's balance sheet, from Q2 2026 back to Q3 2023, across 16 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow OCUL's reporting calendar. What is a balance sheet?